BioSpace News Archive

SCYNEXIS, Inc. announced that Marco Taglietti, President and Chief Executive Officer of SCYNEXIS, will present in person at the upcoming H.C. Wainwright Annual Global Investment Conference and the Ladenburg Thalmann Annual Healthcare Conference.

Immunocore Holdings plc (Nasdaq: IMCR), has released today initial Phase 1 data for the first off-the-shelf ImmTAC® targeting PRAME, demonstrating that IMC-F106C is well tolerated and resulted in durable responses across multiple solid tumor types.

LFB Plasma, a US-based plasma collection company and subsidiary of the LFB Group, a leading European company providing plasma-derived products to healthcare professionals, announces joining the Plasma Protein Therapeutics Association.

Regeneron Pharmaceuticals, Inc. will host a conference call and simultaneous webcast to share updates on the company’s oncology portfolio in conjunction with the European Society for Medical Oncology Annual Congress on Monday, September 12, 2022.

Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that its Chief Executive Officer, Dr. Tiago Reis Marques, will deliver a virtual presentation at the H.C. Wainwright 24th Annual Global Investment Conference.

The board of directors of AbbVie Inc. declared a quarterly cash dividend of $1.41 per share.

Today, Health Canada authorized the use of the Pfizer-BioNTech Comirnaty COVID-19 vaccine in children six months to four years of age.

Interventional electrophysiology has made remarkable advancements in the last decade.

Glaucoma is one of the key causes of blindness, and millions of people suffer with visual impairment from glaucoma with a high incidence in those older than 65 years.

As per Transparency Market Research, the global acute myeloid leukemia market (AML) therapeutics market will grow at a sturdy compound annual growth rate over the forecast period of 2020 to 2030 owing to growing incidence of AML.